SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001193125-23-116502 from Baudax Bio, Inc. (BXRXQ) (CIK 0001780097)

Baudax Bio, Inc. (BXRXQ) (CIK 0001780097)
Date: April 26, 2023 · CIK: 0001780097 · Accession: 0001193125-23-116502

AI Filing Summary & Sentiment

File numbers found in text: 333-271161, 333-2711611

Date
April 26, 2023
Author
Not clearly detected
Form
CORRESP
Company
Baudax Bio, Inc. (BXRXQ) (CIK 0001780097)

Letter

Baudax Bio, Inc.

490 Lapp Road

Malvern, Pennsylvania 19355

April 26, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Industrial Applications and Services

100 F Street, NE

Washington, D.C.

Attn: Jane Park and Celeste Murphy

Re: Baudax Bio, Inc.

Registration Statement on Form S-1

SEC File No. 333-271161

Request for Acceleration

Ms. Park:

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Baudax Bio, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-2711611), as amended (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 5:15 PM, eastern time, on April 26, 2023, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Goodwin Procter LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Goodwin Procter LLP, by calling Justin Platt at (212) 459-7340.

Please feel free to direct any questions or comments concerning this request to Justin Platt, Esq. of Goodwin Procter LLP at (212) 459-7340.

BAUDAX BIO, INC.

By:

/s/ Gerri Henwood

Name:

Gerri Henwood

Title:

President and Chief Executive Officer

Cc: Rachael M. Bushey, Goodwin Procter LLP

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 Baudax Bio, Inc.

490 Lapp Road

 Malvern,
Pennsylvania 19355

 April 26, 2023

VIA EDGAR

 U.S. Securities and Exchange Commission

Division of Corporation Finance

 Office of Industrial
Applications and Services

 100 F Street, NE

 Washington, D.C.
20549

 Attn: Jane Park and Celeste Murphy

Re: Baudax Bio, Inc.

       Registration Statement on Form S-1

       SEC File No. 333-271161

       Request for Acceleration

Ms. Park:

 Pursuant to Rule 461 of Regulation C
of the General Rules and Regulations under the Securities Act of 1933, as amended, Baudax Bio, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-2711611), as amended (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become
effective at 5:15 PM, eastern time, on April 26, 2023, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Goodwin Procter LLP, may request by telephone. Once the Registration Statement has been
declared effective, please orally confirm that event with our counsel, Goodwin Procter LLP, by calling Justin Platt at (212) 459-7340.

Please feel free to direct any questions or comments concerning this request to Justin Platt, Esq. of Goodwin Procter LLP at (212) 459-7340.

BAUDAX BIO, INC.

By:

 /s/ Gerri Henwood

Name:

Gerri Henwood

Title:

President and Chief Executive Officer

 Cc: Rachael M. Bushey, Goodwin Procter LLP